Biphasic Granular Bioinks for Biofabrication of High Cell Density Constructs for Dermal RegenerationVise andre og tillknytning
2025 (engelsk)Inngår i: Advanced Healthcare Materials, ISSN 2192-2640, E-ISSN 2192-2659, Vol. 14, nr 21, artikkel-id 2501430Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
Chronic wounds and severe skin injuries pose significant clinical challenges, as existing treatments like cultured epidermal autografts and tissue engineering strategies fail to regenerate functional dermal tissue effectively. These methods often result in scarring due to poor tissue integration, low cell density, and limited extracellular matrix (ECM) production. Conventional skin tissue engineering relies on time-intensive cell expansion, producing constructs that lack the complexity of native dermal structures. Here, a bioprintable biphasic granular hydrogel bioink (mu Ink) based on cell-laden porous gelatin microcarriers (PGMs) is presented, enabling fabrication of ultra-high cell density constructs that promote ECM production for dermal regeneration in vitro and in vivo. Primary human dermal fibroblasts are cultured and expanded on PGMs in a bioreactor prior mu Ink formulation. The cell-laden PGMs are cross-linked via copper-free click chemistry, creating a shear-thinning granular bioink. The mu Ink is 3D bioprinted into structurally stable constructs with high cell viability. In vivo, the bioprinted constructs supported neovascularization, hydrogel remodeling, and tissue integration over 28 days. Cells maintained their tissue-specific phenotype, proliferated, and produced dermal ECM post-transplantation. The mu Ink offers a promising approach to generating high cell-density constructs for scar-free wound healing and for advancing complex tissue reconstruction.
sted, utgiver, år, opplag, sider
WILEY , 2025. Vol. 14, nr 21, artikkel-id 2501430
Emneord [en]
3D bioprinting; granular bioink; hyaluronan; porous gelatin microcarriers; wound healing
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-215371DOI: 10.1002/adhm.202501430ISI: 001507621200001PubMedID: 40509628Scopus ID: 2-s2.0-105008322164OAI: oai:DiVA.org:liu-215371DiVA, id: diva2:1975373
Merknad
Funding Agencies|Erling-Persson Foundation [2021 008]; Swedish Research Council; Knut and Alice Wallenberg Foundation; European Research Council; Swedish State under the agreement between the government and the county councils [ALFGBG-716621, ALFGBG-971618, RO-986077]; [2021-0097]; [KAW 2021.0186]; [101 044 665 PROTECT]
2025-06-242025-06-242025-09-22